French pharmaceutical giant Sanofi revealed that its experimental dengue vaccine has managed to meet its primary goal during a late stage clinical trial and was found to be highly effective even against the most severe type of the disease.
The trial was conducted in Brazil and Latin America and the researchers revealed that it was 95.5 percent effective in treating severe cases of dengue, including the hemorrhagic type.
AdvertisementMore than 31,000 people from 10 endemic countries from Asia and Latin America took part in the study and the company revealed that the vaccine, claimed to be the world's first against dengue fever, will be made available by the second half of 2015 subject to regulatory approval.
P Suven Life Sciences Starts Phase I Trial for Alzheimerís Drug Diabetes Drugs Offer New Hope for Alzheimerís Patients M
You May Also Like